Skip to main content Accessibility help
×
Home
Hostname: page-component-7ccbd9845f-2c279 Total loading time: 0.245 Render date: 2023-01-31T13:33:52.680Z Has data issue: true Feature Flags: { "useRatesEcommerce": false } hasContentIssue true

Article contents

O-10 - Safety Monitoring Guidelines for Treatments for Major Depressive Disorder

Published online by Cambridge University Press:  15 April 2020

S. Dodd
Affiliation:
Medicine, Deakin University, Sydney, NSW Psychiatry, University of Melbourne, Geelong, VIC, Sydney, NSW
G.S. Malhi
Affiliation:
Psychiatry, University of Sydney, Sydney, NSW
J. Tiller
Affiliation:
Psychiatry, University of Melbourne, Melbourne, VIC, Sydney, NSW
I. Schweitzer
Affiliation:
Psychiatry, University of Melbourne, Melbourne, VIC, Sydney, NSW
I. Hickie
Affiliation:
Brain and Mind Research Institute, University of Sydney, Sydney, NSW
J.P. Khoo
Affiliation:
Toowong Specialist Clinic, Brisbane, QLD, Perth, WA
D.L. Basset
Affiliation:
Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, WA
B. Lyndon
Affiliation:
Psychiatry, University of Sydney, Sydney, NSW
P.B. Mitchell
Affiliation:
Psychiatry, University of New South Wales, Sydney, NSW
G. Parker
Affiliation:
Psychiatry, University of New South Wales, Sydney, NSW
P.B. Fitzgerald
Affiliation:
Psychology and Psychiatry, Monash University, Melbourne, VIC, Australia
M. Udina
Affiliation:
University of Barcelona, Barcelona, Spain
A. Singh
Affiliation:
Psychiatry, University of Melbourne, Geelong, VIC, Sydney, NSW
S. Moylan
Affiliation:
Medicine, Deakin University, Sydney, NSW
F. Giorlando
Affiliation:
Psychiatry, University of Melbourne, Geelong, VIC, Sydney, NSW
C. Doughty
Affiliation:
Public Health and General Practice, University of Otago, Christchurch, New Zealand
C.G. Davey
Affiliation:
Orygen Youth Health Research Centre, Melbourne, VICAustralia
M. Theodoros
Affiliation:
New Farm Clinic, Brisbane, QLD, Australia
M. Berk
Affiliation:
Medicine, Deakin University, Sydney, NSW Psychiatry, University of Melbourne, Geelong, VIC, Sydney, NSW Orygen Youth Health Research Centre, Melbourne, VICAustralia

Abstract

HTML view is not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Antidepressants are amongst the most commonly prescribed classes of drugs and their use continues to grow. Adverse outcomes are part of the landscape in prescribing medications and therefore management of safety issues need to be an integral part of practice.

Objectives

We have developed consensus guidelines for safety monitoring with antidepressant treatments.

Aims

To present an overview of screening and safety considerations for pharmacotherapy of clinical depressive disorders and make recommendations for safety monitoring.

Methods

Data were sourced by a literature search using Medline and a manual search of scientific journals to identify relevant articles. Draft guidelines were prepared and serially revised in an iterative manner until all co-authors gave final approval of content.

Results

A guidelines document was produced after approval by all 19 co-authors. The final document gives guidance on; the decision to treat, baseline screening prior to commencement of treatment, and ongoing monitoring during antidepressant treatment. The guidelines state or reference screening protocols that may detect medical causes of depression as well as screening and monitoring protocols to investigate specific adverse effects associated with antidepressant treatments that may be reduced or identified earlier by baseline screening and agent-specific monitoring after commencing treatment.

Conclusions

The implementation of safety monitoring guidelines for treatment of clinical depression may significantly improve outcome, by improving a patient's overall physical health status.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2012
Submit a response

Comments

No Comments have been published for this article.
You have Access

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

O-10 - Safety Monitoring Guidelines for Treatments for Major Depressive Disorder
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

O-10 - Safety Monitoring Guidelines for Treatments for Major Depressive Disorder
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

O-10 - Safety Monitoring Guidelines for Treatments for Major Depressive Disorder
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *